Inhibition of hypoxia inducible factor 1α causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells

• Published in: International journal of radiation oncology, biology, physics Vol. 55; no. 4; pp. 1027 - 1036
• Main Authors: Dai, Simon, Huang, Mary Lin, Hsu, Chang Y, Chao, K.S.Clifford
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.03.2003; Elsevier
• Subjects: Antisense; Apoptosis; Biological and medical sciences; Chemotherapy; Hypoxia inducible factor-1; Malignant glioma; Medical sciences; Hypoxia inducible factor-1; Malignant glioma; Antisense; Chemotherapy; Apoptosis
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/S0360-3016(02)04507-8

Hypoxia, which activates the hypoxia inducible factor-1 alpha (HIF-1α) pathway, is a common feature in malignant gliomas and has been linked with tumor cell survival and therapy resistance. In this study, we examined the effect of antisense inhibition of HIF-1α on the survival, apoptosis and responses to chemotherapy in U-87 malignant glioma cells. Hypoxia (1% oxygen) was achieved in a tri-gas incubator with intermittent N 2 gas flushing or in a gas tight-module sealed with 94% N 2, 1% O 2 and balance CO 2. HIF-1α inhibition was achieved with antisense phosphorothioate oligodeoxynucleotide (AS-HIF ODN), delivered using cytofectin GSV3815. HIF-1α expression level was monitored by a hypoxia-responsive luciferase reporter assay and verified by northern blot and immunoblot analyses. Cell viability was quantified by a colorimetric microtiter plate MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. Apoptotic cell death was detected with a colorimetric caspase-3 assay, as well as using terminal transferase-catalyzed in situ end labeling (TUNEL) staining. Antisense HIF-1α phosphorothioate oligodeoxynucleotide (AS-HIF ODN) treatment suppressed HIF-1α expression by up to 80% under both normoxic and hypoxic conditions as measured by a hypoxia-responsive reporter assay and confirmed by northern and western blot analyses. Antisense knockdown of HIF-1α resulted in significant reduction in U-87 cells survival and an acceleration of apoptosis, which did not involve p53 transactivation. Pretreatment of cells with Z-Val-Ala-Asp (-OCH 3)-fluoromethylketone (Z-VAD), a broad-spectrum caspase inhibitor largely eliminated this effect of AS-HIF. Caspase-3 specific activity was markedly induced 3 days after AS-HIF treatment when increased cell death was also noted. Transient overexpression of HIF-1α in U-87 cells neutralized apoptosis-inducing effect of AS-HIF. AS-HIF treatment did not affect viability of primary astrocytes and was selectively more toxic to U-87 glioma cells than normal human fibroblasts. The HIF-1α antisense treatment exerted an oxygen-independent, and additive but not synergistic effect to the cytotoxicity of cisplatin, etoposide, and vincristine. These results together indicate that suppression of HIF-1α-expression may be a promising strategy that is selective for reducing the survival and facilitating chemotherapeutic efficacy of malignant glioma.